Vanguard Group
QNCX icon

Vanguard Group’s Quince Therapeutics QNCX Stock Holding History

Vanguard Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.98M Buy
10,420
+1,603
+18% +$807K ﹤0.01% 3128
2025
Q3 		$2.87M Buy
8,817
+1,547
+21% +$515K ﹤0.01% 3460
2025
Q2 		$2.4M Buy
7,270
+841
+13% +$192K ﹤0.01% 3479
2025
Q1 		$1.71M Buy
6,429
+67
+1% +$20.5K ﹤0.01% 3543
2024
Q4 		$2.38M Buy
6,362
+364
+6% +$109K ﹤0.01% 3511
2024
Q3 		$931K Sell
5,998
-75
-1% -$10.7K ﹤0.01% 3795
2024
Q2 		$911K Buy
6,073
+415
+7% +$75K ﹤0.01% 3816
2024
Q1 		$1.2M Buy
5,658
+799
+16% +$199K ﹤0.01% 3750
2023
Q4 		$1.02M Buy
4,859
+109
+2% +$21.8K ﹤0.01% 3822
2023
Q3 		$1.06M Buy
4,750
+284
+6% +$74.2K ﹤0.01% 3808
2023
Q2 		$1.34M Hold
4,466
– – ﹤0.01% 3804
2023
Q1 		$1.39M Buy
4,466
+199
+5% +$38.9K ﹤0.01% 3806
2022
Q4 		$544K Sell
4,267
-93
-2% -$15.6K ﹤0.01% 4074
2022
Q3 		$1.16M Buy
4,360
+420
+11% +$160K ﹤0.01% 3955
2022
Q2 		$1.75M Sell
3,940
-1,697
-30% -$1.2M ﹤0.01% 3861
2022
Q1 		$6.98M Buy
5,637
+252
+5% +$343K ﹤0.01% 3349
2021
Q4 		$13.6M Buy
5,385
+320
+6% +$1.95M ﹤0.01% 3059
2021
Q3 		$92.8M Buy
5,065
+483
+11% +$7.68M ﹤0.01% 2013
2021
Q2 		$48.6M Buy
4,582
+298
+7% +$2.5M ﹤0.01% 2390
2021
Q1 		$30.9M Buy
4,284
+695
+19% +$5M ﹤0.01% 2576
2020
Q4 		$19.9M Buy
3,589
+97
+3% +$859K ﹤0.01% 2631
2020
Q3 		$34.9M Buy
3,492
+493
+16% +$4.48M ﹤0.01% 2198
2020
Q2 		$27.8M Buy
2,999
+753
+34% +$6.9M ﹤0.01% 2272
2020
Q1 		$20.5M Buy
2,246
+188
+9% +$1.86M ﹤0.01% 2273
2019
Q4 		$23.1M Buy
2,058
+891
+76% +$5.38M ﹤0.01% 2462
2019
Q3 		$5.82M Buy
1,167
+293
+34% +$1.8M ﹤0.01% 3083
2019
Q2 		$7.43M Buy
+874
New +$5.22M ﹤0.01% 3023

Other funds holding QNCX

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
SCM
Superstring Capital Management New York $158M AUM 418.32% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group's QNCX Position: Q4 2025 in Review

Vanguard Group increased its Quince Therapeutics (QNCX) stake by 18% in Q4 2025, buying an estimated $807K and bringing the position to 10,420 shares worth $6.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3128.

Vanguard Group first reported a position in QNCX in Q2 2019 and has held it in 27 quarters since. The position peaked at $92.8M in Q3 2021. 62 funds tracked by Wall St. Rank hold QNCX as of Q4 2025.

  • Vanguard Group held 10,420 shares of Quince Therapeutics worth $6.98M as of Q4 2025.
  • Vanguard Group bought 1,603 Quince Therapeutics shares in Q4 2025, an estimated $807K.
  • Quince Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3128 holding.
  • Vanguard Group first reported a position in Quince Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Vanguard Group's Quince Therapeutics position peaked at $92.8M in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.